Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Peginterferon alfa-2a - Roche

Drug Profile

Peginterferon alfa-2a - Roche

Alternative Names: PEG IFN-α-2a; PEG interferon-α-2a; PEG-IFN - Roche; Pegasys; Pegferon; Pegylated interferon-alpha-2a; R 442; RG 442; RG 964; RO 25-8310; RO 253036

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Chugai Pharmaceutical; Icahn School of Medicine at Mount Sinai; Roche; University of Pennsylvania
  • Class Antineoplastics; Antivirals; Interferons; Polyethylene glycols
  • Mechanism of Action Immunostimulants; Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis B; Hepatitis C
  • Phase II HIV-1 infections
  • No development reported Chronic myeloid leukaemia; Essential thrombocythaemia; Hepatitis D; Polycythaemia vera
  • Discontinued Malignant melanoma; Renal cell carcinoma

Most Recent Events

  • 18 Oct 2021 Hoffmann-La Roche completes a phase III trial in Hepatitis B (In adolescents, In children) in United Kingdom, Ukraine, Russia, Poland, Italy, Israel, Germany, China, Bulgaria, Belgium, Australia, USA (SC) (NCT01519960)
  • 08 Apr 2021 Registered for Hepatitis B (In adolescents, In children) in Iceland, Liechtenstein, Norway (SC)
  • 08 Apr 2021 Registered for Hepatitis B (In adolescents, In children) in European Union (SC)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top